TY - JOUR
T1 - Germline mutation landscape of DNA damage repair genes in African Americans with prostate cancer highlights potentially targetable RAD genes
AU - Kohaar, Indu
AU - Zhang, Xijun
AU - Tan, Shyh Han
AU - Nousome, Darryl
AU - Babcock, Kevin
AU - Ravindranath, Lakshmi
AU - Sukumar, Gauthaman
AU - Mcgrath-Martinez, Elisa
AU - Rosenberger, John
AU - Alba, Camille
AU - Ali, Amina
AU - Young, Denise
AU - Chen, Yongmei
AU - Cullen, Jennifer
AU - Rosner, Inger L.
AU - Sesterhenn, Isabell A.
AU - Dobi, Albert
AU - Chesnut, Gregory
AU - Turner, Clesson
AU - Dalgard, Clifton
AU - Wilkerson, Matthew D.
AU - Pollard, Harvey B.
AU - Srivastava, Shiv
AU - Petrovics, Gyorgy
N1 - Publisher Copyright:
© 2022, This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.
PY - 2022/12
Y1 - 2022/12
N2 - In prostate cancer, emerging data highlight the role of DNA damage repair genes (DDRGs) in aggressive forms of the disease. However, DDRG mutations in African American men are not yet fully defined. Here, we profile germline mutations in all known DDRGs (N = 276) using whole genome sequences from blood DNA of a matched cohort of patients with primary prostate cancer comprising of 300 African American and 300 European Ancestry prostate cancer patients, to determine whether the mutation status can enhance patient stratification for specific targeted therapies. Here, we show that only 13 of the 46 DDRGs identified with pathogenic/likely pathogenic mutations are present in both African American and European ancestry patients. Importantly, RAD family genes (RAD51, RAD54L, RAD54B), which are potentially targetable, as well as PMS2 and BRCA1, are among the most frequently mutated DDRGs in African American, but not in European Ancestry patients.
AB - In prostate cancer, emerging data highlight the role of DNA damage repair genes (DDRGs) in aggressive forms of the disease. However, DDRG mutations in African American men are not yet fully defined. Here, we profile germline mutations in all known DDRGs (N = 276) using whole genome sequences from blood DNA of a matched cohort of patients with primary prostate cancer comprising of 300 African American and 300 European Ancestry prostate cancer patients, to determine whether the mutation status can enhance patient stratification for specific targeted therapies. Here, we show that only 13 of the 46 DDRGs identified with pathogenic/likely pathogenic mutations are present in both African American and European ancestry patients. Importantly, RAD family genes (RAD51, RAD54L, RAD54B), which are potentially targetable, as well as PMS2 and BRCA1, are among the most frequently mutated DDRGs in African American, but not in European Ancestry patients.
UR - http://www.scopus.com/inward/record.url?scp=85126694680&partnerID=8YFLogxK
U2 - 10.1038/s41467-022-28945-x
DO - 10.1038/s41467-022-28945-x
M3 - Article
C2 - 35292633
AN - SCOPUS:85126694680
SN - 2041-1723
VL - 13
JO - Nature Communications
JF - Nature Communications
IS - 1
M1 - 1361
ER -